Led by Dr David Chang, the Therapeutic Development Division takes attractive candidate novel therapeutic vulnerabilities from the Translational Bioscience Division and assesses them in the laboratory to build a preclinical platform of evidence to support testing in the clinic.
The Therapeutic Development Division boasts a large array of model systems including 70 patient-derived xenographs and an ever-growing selection of genetically engineered mouse models. Many of these mouse models are developed to mimic the molecular pathology of the human disease in order to test hypothesised therapeutic strategies based on specific molecular vulnerabilities that characterise molecular subtypes of cancer.
Our researchers are working on cancer science that really matters in the real world.
Research Team